Greenhaven Road Investment Management L.P. Has $30 Million Holdings in Lifecore Biomedical, Inc. $LFCR

Greenhaven Road Investment Management L.P. raised its stake in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 2.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 3,694,832 shares of the company’s stock after acquiring an additional 78,686 shares during the period. Lifecore Biomedical accounts for about 10.3% of Greenhaven Road Investment Management L.P.’s portfolio, making the stock its 3rd biggest position. Greenhaven Road Investment Management L.P. owned about 0.10% of Lifecore Biomedical worth $30,002,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Summit Securities Group LLC bought a new position in shares of Lifecore Biomedical during the first quarter valued at about $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Lifecore Biomedical by 14.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock worth $104,000 after buying an additional 1,886 shares in the last quarter. GWN Securities Inc. bought a new position in shares of Lifecore Biomedical in the second quarter valued at approximately $106,000. Intech Investment Management LLC increased its position in shares of Lifecore Biomedical by 62.8% during the second quarter. Intech Investment Management LLC now owns 17,263 shares of the company’s stock valued at $140,000 after acquiring an additional 6,660 shares during the last quarter. Finally, Wittenberg Investment Management Inc. lifted its holdings in Lifecore Biomedical by 40.9% during the second quarter. Wittenberg Investment Management Inc. now owns 17,223 shares of the company’s stock worth $140,000 after acquiring an additional 5,000 shares during the period. Institutional investors own 83.36% of the company’s stock.

Wall Street Analysts Forecast Growth

LFCR has been the subject of a number of recent analyst reports. Wall Street Zen upgraded Lifecore Biomedical from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. KeyCorp started coverage on shares of Lifecore Biomedical in a report on Wednesday, September 3rd. They set a “sector weight” rating for the company. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Lifecore Biomedical in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.00.

Lifecore Biomedical Price Performance

Shares of NASDAQ LFCR opened at $7.77 on Friday. The company has a debt-to-equity ratio of 113.76, a quick ratio of 1.67 and a current ratio of 2.80. Lifecore Biomedical, Inc. has a fifty-two week low of $4.76 and a fifty-two week high of $8.85. The stock has a market cap of $291.14 million, a PE ratio of -7.26 and a beta of 0.60. The stock has a fifty day moving average of $7.18 and a 200-day moving average of $7.33.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings results on Monday, April 1st. The company reported ($0.22) earnings per share for the quarter. Lifecore Biomedical had a negative net margin of 25.59% and a negative return on equity of 1,211.09%. The company had revenue of $26.54 million for the quarter. Equities research analysts anticipate that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current year.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.